• BiomeBank and Hudson Institute sign a 4-year collaboration agreement to discover and develop microbial therapies.
• BiomeBank gains exclusive license to paediatric IBD study, which identified key bacteria believed to be involved in disease onset and resolution. These bacteria were identified using a world-first method that unlocks culturing and metagenomics of colon biopsy samples.
The translation of research into the development of innovative and life-saving microbial therapies is set to transform in Australia through a partnership between Hudson Institute of Medical Research and BiomeBank, a clinical stage microbiome therapeutics company.
A Memorandum of Understanding between the two organisations has been signed, enabling BiomeBank to bring its experience in the discovery and development of microbial therapies to enable translation of Hudson Institute’s microbiome research.
The partnership strengthens Hudson Institute’s business case for an Australian-first National Centre for Inflammation Research (“NCIR”) and will initially focus on the development of defined and targeted microbial therapies to treat unmet medical need for patients with Inflammatory Bowel Disease (“IBD”).
BiomeBank, which has recently launched its Series-A funding round, has signed a four-year collaborative agreement with Hudson Institute to translate current and future microbiome research into microbial therapies. This includes a recent deal granting BiomeBank access to important research on how the microbiota could treat paediatric inflammatory bowel disease, which is unique because the research used culturing and high-resolution microbial analysis of the colon rather than stool samples.
Why the microbiome?
The human microbiome holds the key to how many ailments develop and play out in our body. Humans are mostly made up of microbes — more than 100 trillion of them. Those in the gut, particularly in the large intestine, play an important part in health and disease. Imbalances in our gut microbiome are known to contribute to complex conditions such as inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), allergies, and obesity.
BiomeBank is a clinical stage biotechnology company developing a pipeline of microbiome therapies to treat unmet medical need. BiomeBank’s mission is to treat and prevent disease by restoring gut microbial ecology.
Backed by a world-leading team of translational microbiome experts, BiomeBank’s platform uses a unique combination of machine learning and microbiology to identify bacterial strains which influence disease, leading to the discovery and development of new therapies.
About Hudson Institute
Hudson Institute is home to more than 450 world-class scientists, clinicians and students pioneering outstanding discovery science and translational research.
As a leading Australian biomedical research institute, we convert scientific knowledge into new diagnostics, treatments, and cures.
Our researchers push the boundaries of scientific knowledge in five areas of human health: Inflammation, Reproductive health and pregnancy, Infant and child health, Cancer and Hormonal health.
The National Centre for Inflammation Research at Hudson Institute will harness scientific discoveries to curb the burden of disease, improve health for all Australians, attract international investment and grow Victorian jobs.